Novo Nordisk raised its full-year sales guidance after revenue from its blockbuster Wegovy obesity treatment surged in the second quarter.
Novo Nordisk raised its full-year sales guidance after revenue from its blockbuster Wegovy obesity treatment surged in the second quarter.